Research Topics
Species | Gianantonio RostiSummaryAffiliation: University of Bologna Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti
Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
Blood 114:4933-8. 2009..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...- Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti
Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Italy
Crit Rev Oncol Hematol 82:159-70. 2012..Clinicians now have several effective options to treat patients newly diagnosed with CML-CP and available data suggest that dasatinib and nilotinib represent improved therapeutic options compared with imatinib... - Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLGianantonio Rosti
Department of Hematology and Oncology, L and A Seragnoli, St Orsola University Hospital, University of Bologna, 9 40138 Bologna, Italy
Cancer Treat Rev 38:241-8. 2012..The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy... - Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti
Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
Leuk Lymphoma 51:583-91. 2010..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria... 
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on ChrSimona Soverini
, University of Bologna, Via Massarenti 9-40138 Bologna, Italy
J Clin Oncol 23:4100-9. 2005....- Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini
Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
Haematologica 92:401-4. 2007..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317... - Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti
Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
Blood 120:761-7. 2012..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy... - Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini
, University of Bologna, Bologna, Italy
Clin Cancer Res 12:7374-9. 2006.... - Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
J Clin Oncol 26:106-11. 2008..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial... - Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti
Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
J Clin Oncol 28:2748-54. 2010..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient... - Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga
Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
Expert Opin Biol Ther 7:1597-611. 2007..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases... - Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti
Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
Blood 113:3428-34. 2009..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926... - Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani
Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
Blood 104:4245-51. 2004..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies... 
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
Haematologica 95:1415-9. 2010..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini
Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
Blood 114:2168-71. 2009.... - Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci
, University of Bologna, Bologna, Italy
Clin Cancer Res 12:3037-42. 2006..0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05)... - Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi
Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
Blood 117:6793-800. 2011..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926... - Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci
, University of Bologna, Bologna, Italy
J Clin Oncol 24:454-9. 2006..Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progression-free and overall survival... - The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
Haematologica 92:1173-9. 2007..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate... - Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri
Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 93:770-4. 2008..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance... - Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri
Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 94:1758-61. 2009..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited... - Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Clin Cancer Res 15:1059-63. 2009..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib... - Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini
Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
Leuk Res 35:1527-9. 2011..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse... - Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini
, University of Bologna, Bologna, Italy
Clin Chem 50:1205-13. 2004..It may therefore potentially be a valuable tool for regular, large-scale testing of patients undergoing Imatinib treatment... - Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
Haematologica 92:101-5. 2007..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients... - Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri
Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 93:1792-6. 2008..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients... - Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini
, University of Bologna, Italy
Lancet Oncol 8:273-4. 2007 - New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 90:534-41. 2005..This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance... - Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini
Department of Haematology Oncology, L e A Serígnoli, University of Bologna, Bologna, Italy
Oncologist 16:868-76. 2011..Here, we discuss the pros and cons of using this approach in TKI selection... - Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
Blood 113:4497-504. 2009..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488... - The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 94:205-12. 2009..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available... - Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemiaGianantonio Rosti
L and A Seràgnoli Institute of Hematology and Medical Oncology, St Orsola Malpighi Hospital, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 88:256-9. 2003.... - Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysisSimona Soverini
Department of Hematology Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138, University of Bologna, Bologna, Italy
Pharmacogenomics 13:1271-84. 2012..The authors also discuss the practical relevance of Bcr-Abl mutation analysis and how this tool should best be integrated in the optimal clinical management of chronic myeloid leukemia patients... - Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaGianantonio Rosti
, University of Bologna, Italy
Blood 103:2284-90. 2004..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet... - Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndromeGiovanni Martinelli
, University of Bologna, Italy
Haematologica 89:236-7. 2004 - Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni
Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
Blood 114:4939-43. 2009..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926... - Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intoleranceGiovanni Martinelli
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
Biologics 1:121-7. 2007..Preliminary studies demonstrated that nilotinib has more efficacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profile and clinical efficacy in all phases of CML... - BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini
Department of Hematology Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
Blood 118:1208-15. 2011..In all the cases outlined within this abstract, a positive result is an indication for therapeutic change. Some specific mutations weigh on TKI selection... - Imatinib in chronic myeloid leukemia elderly patientsGabriele Gugliotta
Department of Hematology and Clinical Oncology Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
Aging (Albany NY) 3:1125-6. 2011..Although data on dasatinib and nilotinib in elderly patients are still few and the follow-up is still short, these second generation tyrosine kinase inhibitors will probably further improve the outcome of CML elderly patients... - Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli
Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 87:688-94; discussion 694. 2002..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others... - First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationPier Paolo Piccaluga
Hematopathology and Hematology Sections, Department of Hematology and Oncological Sciences, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
J Blood Med 3:151-6. 2012..In this paper, we review the most relevant data on nilotinib as first-line treatment for CML, and discuss the rationale for its routine use, as well as some possible future perspectives for CML patients... - A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemiaMichele Baccarani
L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
Blood 99:1527-35. 2002....